A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL-Ⅱ With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions(CREDIT-I)

JW Medical Systems Ltd1 site in 1 country45 target enrollmentJanuary 2013

ConditionsIschemia Coronary Artery Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Ischemia
Sponsor: JW Medical Systems Ltd
Enrollment: 45
Locations: 1
Primary Endpoint: Primary endpoint(MACE)
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

One of the purpose of this study is to assess the preliminary safety and feasibility,and to provide related information and evidence for the design of the further pivotal randomized control trial.the other purpose is to assess the performace of the stent delivery system.

Detailed Description

1. Single-center, prospective, pilot study 2. De novo,coronary artery, single vessel and single lesion 3. Sample size = 45 4. Follow- up clinical or phone at 1-month,9-month and annually 2 to 5 years 5. Randomization 2:1 Angio and OCT scheduled follow-up in the hospital 6. Follow-up Angio and OCT randomized 30 patients for 4-month and 15 patiens for 12-month

Registry

clinicaltrials.gov

Start Date

January 2013

End Date

June 4, 2019

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

JW Medical Systems Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•18yrs≤Age≤75yrs .
•De novo lesion at native coronary artery.
•Single target vessel and single target lesion.
•Lesion length ≤32mm.
•RVD 2.5mm～4.0mm.
•DS%≥70% by visual estimation.
•Target lesion could be covered by only one stent.
•Subjects are willing to follow the specified requirements follow-up.
•A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.

Exclusion Criteria

•AMI within one week.
•CTO(TIMI0),LM lesion,ostial lesion,graft vessel lesion,bifurcation (side branch RVD≥2.5mm),ISR,mutivessel disease need to be treated.
•Severe calcified lesion unable to predilate.
•extremely tortuous proximal to the lesion that is inadequate to stent delivery.
•NYHA≥Ⅲ or LVEF≤40%.
•Prior stenting within 1 year.
•Pregnancy or lactation, and plan in postoperative pregnancy or lactation.
•Subjects had bleeding tendency or blood coagulation dysfunction or PCI contraindications, or anticoagulant therapy taboo or can't continue DAPT healers at least 1 year.
•There are other diseases (such as cancer,malignant tumor ,congestive heart failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin, etc.), scheme compliance is poor, interference related data explanation or the limited life (\< 1 year).
•To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent of one of allergy.

Outcomes

Primary Outcomes

Primary endpoint(MACE)

Time Frame: 30days(MACE)

Device oriented cardiovascular endpoint at 30-day (MACE) defined as the composite of Cardiac Death,Myocardial Infarction(Q and non-Q) or Ischemia-driven Target Lesion Revascularization